肝硬化合并COVID-19患者与单纯肝硬化及单纯COVID-19患者死亡风险的比较:多中心匹配队列研究
这项多中心匹配队列研究纳入37例肝硬化合并COVID-19住院患者,与108例单纯COVID-19和127例单纯肝硬化患者按年龄/性别匹配。肝硬化合并COVID-19患者死亡率30%,高于单纯COVID-19患者的13%(p=0.03),但与单纯肝硬化患者的20%相比无显著差异(p=0.16)。在整个匹配队列中,Charlson合并症指数(OR 1.23,95%CI 1.11至1.37,p<0.0001)是唯一预测死亡率的变量。
要点
- 肝硬化合并COVID-19患者死亡率30%,高于单纯COVID-19患者的13%(p=0.03)。
- 肝硬化合并COVID-19与单纯肝硬化患者死亡率30% vs 20%相比无显著差异(p=0.16)。
- 整个队列中Charlson合并症指数是唯一独立预测死亡率的变量(OR 1.23)。
核心结论
- 在这项北美多中心同期入组研究中,年龄/性别匹配的肝硬化合并COVID-19患者死亡率与单纯肝硬化患者相似,但高于单纯COVID-19患者。
- 在整个匹配队列中,Charlson合并症指数是唯一独立预测死亡率的变量。
研究设计与样本
- 多中心研究,纳入肝硬化合并COVID-19住院患者37例,与年龄/性别匹配的单纯COVID-19患者108例和单纯肝硬化患者127例进行比较,来自七个中心。
- 比较COVID-19和肝硬化特征、器官衰竭和慢加急性肝衰竭(ACLF)的发生以及死亡率(住院死亡+临终关怀)。
主要发现
- 肝硬化合并COVID-19患者死亡率30%,单纯COVID-19患者13%,差异有统计学意义(p=0.03)。
- 肝硬化合并COVID-19患者死亡率30%,单纯肝硬化患者20%,差异无统计学意义(p=0.16)。
- 肝硬化合并COVID-19患者与单纯COVID-19患者呼吸道症状、胸部表现、ICU转运率和通气率相当。
- 肝硬化合并COVID-19患者Charlson合并症指数(CCI)较单纯COVID-19患者更差(6.5±3.1 vs 3.3±2.5,p<0.001),就诊时胃肠道症状更少,乳酸更高。
- 单纯肝硬化患者较肝硬化合并COVID-19患者肝硬化相关并发症更多、最高MELD评分更高、BiPAP/通气需求更低,但CCI和ACLF发生率相似。
关键数值与推荐
- 整个队列多变量回归中,CCI预测死亡率的OR为1.23(95%CI 1.11至1.37,p<0.0001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Comorbid conditions are associated with poor prognosis in COVID-19. Registry data show that patients with cirrhosis may be at high risk. However, outcome comparisons among patients with cirrhosis+COVID-19 versus patients with COVID-19 alone and cirrhosis alone are lacking. The aim of this study was to perform these comparisons. DESIGN: A multicentre study of inpatients with cirrhosis+COVID-19 compared with age/gender-matched patients with COVID-19 alone and cirrhosis alone was performed. COVID-19 and cirrhosis characteristics, development of organ failures and acute-on-chronic liver failure (ACLF) and mortality (inpatient death+hospice) were compared. RESULTS: 37 patients with cirrhosis+COVID-19 were matched with 108 patients with COVID-19 and 127 patients with cirrhosis from seven sites. Race/ethnicity were similar. Patients with cirrhosis+COVID-19 had higher mortality compared with patients with COVID-19 (30% vs 13%, p=0.03) but not between patients with cirrhosis+COVID-19 and patients with cirrhosis (30% vs 20%, p=0.16). Patients with cirrhosis+COVID-19 versus patients with COVID-19 alone had equivalent respiratory symptoms, chest findings and rates of intensive care unit transfer and ventilation. However, patients with cirrhosis+COVID-19 had worse Charlson Comorbidity Index (CCI 6.5±3.1 vs 3.3±2.5, p<0.001), lower presenting GI symptoms and higher lactate. Patients with cirrhosis alone had higher cirrhosis-related complications, maximum model for end-stage liver disease (MELD) score and lower BiPAP/ventilation requirement compared with patients with cirrhosis+COVID-19, but CCI and ACLF rates were similar. In the entire group, CCI (OR 1.23, 95% CI 1.11 to 1.37, p<0.0001) was the only variable predictive of mortality on multivariable regression. CONCLUSIONS: In this multicentre North American contemporaneously enrolled study, age/gender-matched patients with cirrhosis+COVID-19 had similar mortality compared with patients with cirrhosis alone but higher than patients with COVID-19 alone. CCI was the only independent mortality predictor in the entire matched cohort.
引用
- Bajaj JS, Garcia-Tsao G, Biggins SW, et al. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut. 2020. PMID: 32660964. doi:10.1136/gutjnl-2020-322118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。